The present invention provides a compound of formula (Ia) or (Ib) or a stereoisomer,
tautomer or pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , X 3 and X 4 Each independently is CR 6 or N; its premise is X 1 , X 2 , X 3 or X 4 No more than two of them are N; L is 0 to 4 R 7 Substituted C 1‑4 Alkylene; R 1 (‑CH 2 ) a R 9 ; a is an integer 0 or 1; R 2 are independently
halogen, cyano, hydroxyl, amino, C 1‑6
Alkyl, C 3‑6 Cycloalkyl, C 4‑6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl or haloalkoxy; n is an integer of 0, 1 or 2; R 3 For
hydrogen, C 1‑6
Alkyl, C 1‑6 deuterated
alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy, and the
alkyl itself or as part of other moieties is optionally partially or fully substituted with
deuterium; R 4 C 1‑10
Alkyl, C 1‑10 Deuterated
alkyl, C 1‑10 Haloalkyl, C 1‑10 Alkenyl, C 3‑8 Cycloalkyl, 6- to 10-membered
aryl, 3- to 8-membered heterocyclic group, -(C 1‑6 Alkylene)‑(C 3‑8 Cycloalkyl), -(C 1‑6 alkylene)-(6 to 10 membered
aryl),-(C 1‑6 alkylene)-(3 to 8 membered heterocyclic group) or-(C 1‑6 wherein each of the alkyl, alkylene, alkenyl, cycloalkyl,
aryl, heterocyclyl and heteroaryl groups is independently substituted by 0 to 3 R 8 Replace; or, R 3 and R 4 Together with the N atom to which it is attached, it forms a 8 Substituted 4 to 9 membered heterocyclic
moiety; R 5 and R 6are independently
hydrogen,
halogen, cyano, hydroxyl, amino, C 1‑6 Alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy; R 7 is
halogen, oxo, cyano, hydroxyl, amino, C 1‑6 Alkyl, C 3‑6 Cycloalkyl, C 4‑6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy; R 8 are independently
deuterium, halogen, hydroxyl, amino, cyano, C 1‑6 Alkyl, C 1‑6 Deuterated alkyl, C 2‑6 Alkenyl, C 2‑6 alkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5- to 6-membered heteroaryl; or, two R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered carbocyclic ring or a 3- to 6-membered heterocyclic ring, each of which is independently substituted by 0 to 3 R 12 Replacement; R 9 Selected from ‑CN, ‑C(O)OR 10 ,‑C(O)NR 11a R 11b , ‑CO‑NH‑CO‑R e , ‑CO‑NH‑SO 2 ‑R e , ‑CO‑NH‑SO‑R e ,‑SO 2 ‑OH, ‑SO 2 NH-CO-R e , ‑P(O)(OH) 2 , tetrazol-5-yl, -CH 2 ‑CO‑NH‑CO‑R e ,‑CH 2 ‑CO‑NH‑SO 2 ‑R e , CH 2 ‑CO‑NH‑SO‑R e ,‑CH 2 ‑SO 2 ‑OH, ‑CH 2 ‑SO 2 NH-CO-R e ,‑CH 2 ‑P(O)(OH) 2 , tetrazol-5-ylmethylene, R e C 1‑6 Alkyl, C 3‑6Cycloalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl or haloalkoxyalkyl; R 10 is
hydrogen or C 1‑10 Alkyl; and R 11a and R 11b are independently hydrogen, C 1‑6 Alkyl, C 3‑6 Cycloalkyl, C 4‑6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy; and R 12 For halogen, cyano, hydroxyl, amino, C 1‑6 Alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl or 5- to 6-membered heteroaryl. These compounds are selective LPA
receptor inhibitors. #imgabs0#